Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Yuko Tsuchiya-Kawano"'
Autor:
Taishi Harada, Tomonari Sasaki, Hidenobu Ishii, Shinnosuke Takemoto, Yasushi Hisamatsu, Haruhiro Saito, Yasuto Yoneshima, Kazutoshi Komiya, Kosuke Kashiwabara, Katsuhiko Naoki, Tomohiro Ogawa, Hiroaki Takeoka, Koichi Saruwatari, Kensaku Ito, Yuko Tsuchiya‐Kawano, Keiko Mizuno, Takayuki Shimose, Yoshiyuki Shioyama, Isamu Okamoto
Publikováno v:
Thoracic Cancer, Vol 15, Iss 29, Pp 2128-2135 (2024)
Abstract Background Concurrent chemoradiotherapy is the standard therapy for locally advanced non‐small cell lung cancer (NSCLC). However, there is little evidence supporting its use in older adults. Low‐dose daily carboplatin combined with thora
Externí odkaz:
https://doaj.org/article/02abb0ebf4f841608cfd2dd4a19fea88
Autor:
Soichiro Sakoda, Kentaro Tanaka, Yuichiro Koga, Hironori Mikumo, Yuko Tsuchiya‐Kawano, Eiji Harada, Sadafumi Tamiya, Isamu Okamoto
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 415-418 (2024)
Abstract Metastatic inflammatory myofibroblastic tumor (IMT) is very rare and detailed reports on diagnosis and treatment are limited. Here, we report a case of metastatic IMT with ALK rearrangement. A 73‐year‐old woman was diagnosed with IMT inv
Externí odkaz:
https://doaj.org/article/83ab994b16d84da982e1f4ab5ed73ce1
Autor:
Kazushige Wakuda, MD, Hiroyuki Yamaguchi, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Minoru Fukuda, MD, PhD, Kentaro Ito, MD, Yuko Tsuchiya-Kawano, MD, PhD, Kentaro Tanaka, MD, PhD, Taishi Harada, MD, PhD, Yuki Nakatani, MD, Satoru Miura, MD, Toshihide Yokoyama, MD, Tomomi Nakamura, MD, Miiru Izumi, MD, PhD, Atsushi Nakamura, MD, PhD, Satoshi Ikeda, MD, PhD, Koichi Takayama, MD, PhD, Kenichi Yoshimura, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kenji Sugio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100587- (2023)
Introduction: Osimertinib may be effective in treating central nervous system (CNS) metastasis, but its efficacy in treating radiation therapy (RT)-naive metastasis is unclear. The OCEAN study assessed the efficacy of osimertinib against RT-naive CNS
Externí odkaz:
https://doaj.org/article/2430d3ab5e8943f5b2079f35a13f2fad
Autor:
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, Takahiro Yoshizawa, Masafumi Saiki, Yuichi Tambo, Junji Koyama, Masaki Kanazu, Keita Kudo, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 14, Iss 2, Pp 168-176 (2023)
Abstract Background The therapeutic efficacy of cytotoxic anticancer drugs has been reported to be enhanced after immune checkpoint inhibitors (ICI) in non–small cell lung cancer; however, it is unclear whether the same is applicable for small cell
Externí odkaz:
https://doaj.org/article/8194827c78724e359bab2959b6fa2bc1
Autor:
Kazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, Shinichiro Shimamatsu, Fumihiko Hirai, Tetsuzo Tagawa, Tatsuro Okamoto, Motoharu Hamatake, Yuko Tsuchiya-Kawano, Kohei Otsubo, Koji Inoue, Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto, Yoichi Nakanishi, Masaki Mori
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Many studies have recently reported the association of concomitant medications with the response and survival in patients with non-small-cell lung cancer (NSCLC) treated with cancer immunotherapy. However, the clinical impact of s
Externí odkaz:
https://doaj.org/article/7ffb67434519442782c281e291c67c5b
Autor:
Hisashi Tanaka, Hiroaki Sakamoto, Takahiro Akita, Fumiyoshi Ohyanagi, Yosuke Kawashima, Yuichi Tambo, Azusa Tanimoto, Atsushi Horiike, Eisaku Miyauchi, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 13, Iss 10, Pp 1471-1478 (2022)
Abstract Background Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs are often re‐administered in Japan after the disease p
Externí odkaz:
https://doaj.org/article/5e5f715847fd4a66aa35dd6d0e976bda
Autor:
Toshifumi Ninomiya, Kohei Otsubo, Teppei Hoshino, Mototsugu Shimokawa, Megumi Nakazawa, Yoriko Sato, Hironori Mikumo, Satoru Kawakami, Shun Mizusaki, Yusuke Mori, Hidenobu Arimura, Yuko Tsuchiya-Kawano, Koji Inoue, Yujiro Uchida, Yoichi Nakanishi
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Although the risk factors for coronavirus disease 2019 (COVID-19) mortality have been identified, there is limited information about the risk factors for disease progression after hospitalization among Japanese patients with COVID
Externí odkaz:
https://doaj.org/article/883fabbfbceb4c97abebbd2341c4f1a8
Autor:
Tsukasa Hasegawa, Ryo Ariyasu, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Atsushi Horiike, Toshio Sakatani, Takehiro Tozuka, Jun Shiihara, Masafumi Saiki, Yuichi Tambo, Tomoaki Sonoda, Akito Miyazaki, Shinya Uematsu, Yuko Tsuchiya-Kawano, Noriko Yanagitani, Makoto Nishino
Publikováno v:
Cancer Chemotherapy and Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c31a976d3d9a51bd3f7aaf6bfd44d4ff
https://doi.org/10.1007/s00280-023-04547-2
https://doi.org/10.1007/s00280-023-04547-2
Autor:
Hisashi Tanaka, Hiroaki Sakamoto, Takahiro Akita, Fumiyoshi Ohyanagi, Yosuke Kawashima, Yuichi Tambo, Azusa Tanimoto, Atsushi Horiike, Eisaku Miyauchi, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer. 13:1471-1478
Dacomitinib is the second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC). EGFR-TKIs are often re-administered in Japan after the disease progression prior EGFR-TKI. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e50b03e834fc679d2af36700d8c9e3c
https://doi.org/10.1111/1759-7714.14415
https://doi.org/10.1111/1759-7714.14415
Autor:
Yoshimasa Shiraishi, Takayuki Shimose, Yuko Tsuchiya-Kawano, Hidenobu Ishii, Haruko Daga, Kentaro Ito, Koichi Saruwatari, Isamu Okamoto
Publikováno v:
Cancer Management and Research.
Yoshimasa Shiraishi,1 Takayuki Shimose,2 Yuko Tsuchiya-Kawano,3 Hidenobu Ishii,4 Haruko Daga,5 Kentaro Ito,6 Koichi Saruwatari,7 Isamu Okamoto1 1Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab35859f149d531c78a6e70b6142fb63
https://www.dovepress.com/forthcoming-phase-ii-study-of-durvalumab-medi4736-plus-chemotherapy-fo-peer-reviewed-fulltext-article-CMAR
https://www.dovepress.com/forthcoming-phase-ii-study-of-durvalumab-medi4736-plus-chemotherapy-fo-peer-reviewed-fulltext-article-CMAR